ClinicalTrials.gg
RecruitingNCT06840119Updated Jan 28, 2026

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

A Phase 1/2 interventional study of IMC-R117C and Chemotherapy drug in Cancer and HLA-A*02:01-positive, sponsored by Immunocore Ltd. Recruiting at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Immunocore Ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2024, registered Feb 2025).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
600
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A*02:01-positive participants with selected advanced PIWIL1-Positive cancers.

02

Conditions studied

  • Cancer
  • HLA-A*02:01-positive

Browse trials for

03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 600 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Immunocore Ltd is the lead sponsor of 15 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status score of 0 or 1
  • HLA-A*02:01-positive
  • confirmed advanced colorectal, esophageal, gastric, or ovarian carcinoma
  • Archived or fresh tumor tissue sample that must be confirmed as adequate
  • Evaluable/ per 1.1
  • Previously received applicable standard treatments
  • Male and female participants of who are sexually active with a non-sterilized partner must agree to use highly effective methods of

Exclusion criteria

Exclusion Criteria:

  • Symptomatic or untreated central nervous system
  • Recent bowel obstruction
  • Ongoing ascites or effusion requiring recent drainages
  • Significant ongoing toxicity from prior anticancer treatment
  • Out-of-range laboratory values
  • lung, heart, or disease
  • Ongoing requirement for treatment
  • Significant secondary
  • to study drug or
  • Pregnant or lactating
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Arm A: IMC-R117C Monotherapy Dose-Escalation

    Participants receive IMC-R117C intravenous (IV) infusion.

    Drug: IMC-R117C

  • Experimental
    Arm B: IMC-R117C Combination Dose-Escalation

    Participants receive IMC-R117C IV infusion in combination with standard of care chemotherapy and antiangiogenic agent

    Drug: IMC-R117C · Drug: Chemotherapy drug · Drug: Antiangiogenic Agent

  • Experimental
    Arm C: IMC-R117C Combination Dose-Escalation

    Participants receive IMC-R117C IV infusion with targeted therapies

    Drug: IMC-R117C · Drug: Kinase inhibitor · Drug: Monoclonal antibody

  • Active comparator
    Arm D: Control Arm

    Participants receive standard of care chemotherapy and antiangiogenic agent

    Drug: Chemotherapy drug · Drug: Antiangiogenic Agent

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Percentage of participants with ≥1 dose-limiting toxicity (DLT)

    Time frame: Up to ~24 months

  2. Dose Escalation: Percentage of participants with ≥1 adverse event (AE)

    Time frame: Up to ~24 months

  3. Dose Escalation: Percentage of participants with ≥1 serious adverse event (SAE)

    Time frame: Up to ~24 months

  4. Dose Escalation: Percentage of participants with significant changes in electrocardiogram (ECG) recordings

    Time frame: Up to ~24 months

  5. Dose Escalation: Percentage of participants with significant changes in vital signs

    Time frame: Up to ~24 months

  6. Dose Escalation: Percentage of participants with significant changes in laboratory results

    Time frame: Up to ~24 months

  7. Dose Escalation: Percentage of participants with a dose interruption, reduction, or discontinuation

    Time frame: Up to ~24 months

  8. Expansion: Best Overall Response (BOR) as Determined by RECIST v1.1

    Time frame: Up to ~24 months

Secondary outcomes

  1. Dose Escalation: Best Overall Response (BOR) as Determined by RECIST v1.1 with IMC-R117C Monotherapy and in Combination

    Time frame: Up to ~36 months

  2. Dose Escalation: Duration of Response (DOR) as Determined by RECIST v1.1 with IMC-R117C Monotherapy and in Combination

    Time frame: Up to ~36 months

  3. Dose Escalation: Progression-free survival (PFS) as Determined by RECIST v1.1 with IMC-R117C Monotherapy and in Combination

    Time frame: Up to ~36 months

  4. Dose Escalation: Overall Survival (OS) with IMC-R117C Monotherapy and in Combination

    Time frame: Up to ~36 months

  5. Expansion: Duration of Response (DOR) as Determined by RECIST v1.1 with IMC-R117C Monotherapy

    Time frame: Up to ~36 months

  6. Expansion: Progression-free survival (PFS) as Determined by RECIST v1.1 with IMC-R117C Monotherapy

    Time frame: Up to ~36 months

  7. Expansion: Overall Survival (OS) with IMC-R117C Monotherapy

    Time frame: Up to ~36 months

  8. Expansion: Percentage of participants with ≥1 Adverse Events (AE)

    Time frame: Up to ~24 months

  9. Expansion: Percentage of participants with ≥1 Serious Adverse Events (SAE)

    Time frame: Up to ~24 months

  10. Expansion: Percentage of participants with significant changes in electrocardiogram (ECG) recordings

    Time frame: Up to ~24 months

  11. Expansion: Percentage of participants with significant changes in vital signs

    Time frame: Up to ~24 months

  12. Expansion: Percentage of participants with significant changes in laboratory findings

    Time frame: Up to ~24 months

  13. Expansion: Percentage of participants with dose interruptions, reductions, or discontinuation

    Time frame: Up to ~24 months

  14. All Study: Plasma Concentration of IMC-R117C

    Time frame: Up to ~36 months

  15. All Study: Incidence of anti-IMC-R117C Antibody Formation

    Time frame: Up to ~36 months

  16. All Study: Incidence of tumor expression and localization of PIWIL1

    Time frame: Up to ~36 months

07

Study locations

12 of 13 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Nov 2026, 34 months after the start.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 34 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 21, 2025
StartActual
Jan 10, 2024
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2027
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06840119
Lead sponsor
Immunocore Ltd
Responsible party
Sponsor
First posted
Feb 21, 2025
Start date
Jan 10, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Jan 28, 2026

Study contacts

Immunocore Medical Information
Contact
medical.information@immunocore.com
844-466-8661
Immunocore Medical Information EU
Contact
medinfo.eu@immunocore.com
+00 800-744-51111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Angiogenesis inhibitors

Start the discussion